Genetic Technologies Limited announced a partnership with the Gold Coast Private Hospital (GCPH), a member of Healthscope, to establish a Precision Medicine Clinic at the hospital. Highlights: Panershship will be initiated with a 50-patient pilot study to establish worlow and patient reporting. Pilot study will utilise geneType Multi-risk test combined with Pharmacogenomics (PGx) tests, providing a comprehensive wellness profile for GCPH patients.

Patient recruitment to commence immediately. Positive outcomes could enable the rollout of additional Precision Medicine Clinics throughout the Healthscope network. Gold Coast Private Hospital by Healthscope is a 336 bed, 22 theatre hospital and home to leading doctors and surgeons from around the world.

Healthscope is Australia's only national private hospital operation and healthcare provider with a network of 42 hospitals that service every state and territory with 19,000 employees. According to the US Food and Drug Administration (FDA), Precision Mecine, also known as "personalised medicinine" is an innovative approach to tailoring disease prevention and treatment that takes into account differences in people's genes, environments, and lifestyles. The goal of precision medicine is to target the right treatments to the right patients at the right time.

Utilising GTG's geneType Multi-test and PGx tests will be an important step in improving health outcomes for GCPH's patients.